At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 7 enrolled
Drug / intervention
DEN vaccine F17biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II, Open, Five-year, Clinical Follow-up Study of Thai Children Who Participated in Dengue-003 ("A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children") With Evaluation of a Booster Dose Given One Year After Primary DEN Vaccination Series
U.S. Army Medical Research and Development Command·interventional·Posted Apr 30, 2013·Updated Nov 26, 2018
In Brief
A Phase 2 clinical trial evaluating DEN vaccine F17 for Dengue. Completed, enrolled 7 participants across 1 site.
Detailed Summary
One year follow-up on immunogenicity and safety of a booster dose of DEN vaccine administered approx. 1 year following the second dose
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDengue
CountriesThailand
CollaboratorsGlaxoSmithKline
Timeline
Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2005
Primary CompletionFeb 2005
Study CompletionFeb 2009
First PostedApr 2013
TodayJul 2026
First PostedApr 30, 2013
Enrollment StartFeb 1, 2005
Primary CompletionFeb 1, 2005
Study CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 13.2 years ago
Interventions
DEN vaccine F17biological
The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).